ingenol mebutate - Profile

What are the generic drug sources for ingenol mebutate and what is the scope of patent protection?

Ingenol mebutate is the generic ingredient in two branded drugs marketed by Padagis Israel and Leo Labs, and is included in three NDAs. There are twelve patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Ingenol mebutate has thirty-five patent family members in twenty-one countries.

There is one tentative approval for this compound.

Summary for ingenol mebutate

International Patents:	35
US Patents:	12
Tradenames:	2
Applicants:	2
NDAs:	3
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ingenol mebutate

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ingenol mebutate

Dosage:

GEL;TOPICAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Generic filers with tentative approvals for INGENOL MEBUTATE

Applicant	Application No.	Strength	Dosage Form
		0.05%	GEL; TOPICAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for INGENOL MEBUTATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
PICATO	Gel	ingenol mebutate	0.015%	202833	2	2016-01-27

US Patents and Regulatory Information for ingenol mebutate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Padagis Israel	INGENOL MEBUTATE	ingenol mebutate	GEL;TOPICAL	209018-001	Jan 7, 2019		DISCN	No	No
Padagis Israel	INGENOL MEBUTATE	ingenol mebutate	GEL;TOPICAL	209019-001	Jan 9, 2019		DISCN	No	No
Leo Labs	PICATO	ingenol mebutate	GEL;TOPICAL	202833-001	Jan 23, 2012		DISCN	Yes	No
Leo Labs	PICATO	ingenol mebutate	GEL;TOPICAL	202833-001	Jan 23, 2012		DISCN	Yes	No
Leo Labs	PICATO	ingenol mebutate	GEL;TOPICAL	202833-001	Jan 23, 2012		DISCN	Yes	No

Expired US Patents for ingenol mebutate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Leo Labs	PICATO	ingenol mebutate	GEL;TOPICAL	202833-001	Jan 23, 2012
Leo Labs	PICATO	ingenol mebutate	GEL;TOPICAL	202833-001	Jan 23, 2012
Leo Labs	PICATO	ingenol mebutate	GEL;TOPICAL	202833-002	Jan 23, 2012
Leo Labs	PICATO	ingenol mebutate	GEL;TOPICAL	202833-002	Jan 23, 2012
Leo Labs	PICATO	ingenol mebutate	GEL;TOPICAL	202833-001	Jan 23, 2012

EU/EMA Drug Approvals for ingenol mebutate

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
LEO Laboratories Ltd.	Picato	ingenol mebutate	EMEA/H/C/002275Picato is indicated for the cutaneous treatment of non‑hyperkeratotic, non‑hypertrophic actinic keratosis in adults.	Withdrawn	no	no	no	2012-11-15

International Patents for ingenol mebutate

Country	Patent Number	Title	Estimated Expiration
Cyprus	1115292
World Intellectual Property Organization (WIPO)	2007068963
Israel	192221	תכשירים רפואיים המכילים angelate- 3- ingenol (Therapeutic compositions comprising ingenol-3-angelate)
South Korea	101451993
Poland	1988877

Supplementary Protection Certificates for ingenol mebutate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1015413	C01015413/01	Switzerland		PRODUCT NAME: INGENOLMEBUTAT; REGISTRATION NO/DATE: SWISSMEDIC 62763 12.06.2013
1988877	C01988877/01	Switzerland		PRODUCT NAME: INGENOLMEBUTAT; REGISTRATION NO/DATE: SWISSMEDIC 62763 12.06.2013
1988877	132014902287215	Italy		PRODUCT NAME: INGENOLO MEBUTATO O UN SUO DERIVATO (SALE O ESTERE)(PICATO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/12/796/001-002, 20121119
1988877	2014C/045	Belgium		PRODUCT NAME: MEBUTATE D'INGENOL OU L'UN DE SES DERIVES (SELS OU ESTER); AUTHORISATION NUMBER AND DATE: EU/1/12/796 20121119
1988877	C201430051	Spain		PRODUCT NAME: INGENOL MEBUTATO O UN DERIVADO ESTER DEL MISMO.; NATIONAL AUTHORISATION NUMBER: EU/1/12/796; DATE OF AUTHORISATION: 20121115; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/12/796; DATE OF FIRST AUTHORISATION IN EEA: 20121115

Last updated: February 3, 2026

What is the current investment landscape for ingenol mebutate?

Ingenol mebutate is a topical agent approved for actinic keratosis (AK). It has limited indications, primarily serving niche dermatology markets. The product's market size is constrained by its specific use case and competition from other AK treatments, like 5-fluorouracil, imiquimod, and diclofenac. Its niche application results in moderate sales figures; in 2022, global sales approximated $250 million, reflecting a saturated and competitive landscape. Major suppliers include LEO Pharma, which holds the original approval and marketing rights.

Investment risks stem from patent expiry, generic entry, and regulatory challenges. The expiration date for patent exclusivity is March 2026, raising prospects for generic competitors that could depress prices and erode margins. Companies investing in R&D for analogs or new indications face high costs with uncertain payoff.

How does the manufacturing and patent situation affect the investment outlook?

Ingenol mebutate’s patent estate is limited. Its primary patent expires in 2026, opening the door for generic versions. Patent challenges are imminent, and legal disputes could further influence exclusivity. Manufacturing involves synthesis of complex botanical derivatives, with a moderate cost structure. Production relies heavily on standardized extraction processes, implying scalability within existing frameworks.

Market exclusivity duration is limited to a few years post-patent expiry, with opportunities for patent extensions if new formulations or delivery mechanisms are developed. Companies investing in reformulations, such as liposomal delivery, may extend market longevity.

What is the competitive landscape?

Competitors develop alternative AK treatments with broader market acceptance or better safety profiles. For instance, 5-fluorouracil, 5% imiquimod cream, and diclofenac gel dominate due to longer safety records and longer histories of use. These alternatives often exhibit lower costs and are well-integrated into clinical practice guidelines.

New entrants are focusing on combination therapies or combination devices to improve efficacy or reduce treatment durations. Additionally, the pipeline includes systemic agents under investigation for off-label uses, but none have demonstrated clear market dominance within the AK segment.

What are the regulatory hurdles and approval prospects?

Ingenol mebutate had its original approval from FDA (2009) and EMA (2012). Future regulatory actions depend on post-market safety data, especially concerning rare adverse events such as skin necrosis. Any Novel formulations must undergo rigorous clinical trials, increasing R&D costs. The upcoming patent expiry will further pressure manufacturers to demonstrate the added value of proprietary formulations.

Regulatory agencies are increasingly scrutinizing topical agents for long-term safety. A new indication approval for a broader dermatological application could extend patent life and provide a growth avenue, but such expansions are uncertain and require extensive investment.

How do R&D and pipeline options impact fundamentals?

Limited pipeline activity exists for ingenol mebutate analogs or new dermatology indications. R&D costs for reformulation or new uses are high, and success rates are low. Companies with existing dermatology portfolios may leverage their expertise to formulate combination products or develop derivatives, potentially offsetting patent expiration effects.

Investing solely in current formulations is risky due to patent expiry. Focus shifts to pipeline development or licensing agreements with biotech firms. Strategic alliances can reduce R&D costs but dilute potential returns.

What are the financial implications for investors?

Current revenues are stable but face decline post-2026 due to patent loss. Market share could diminish sharply if generic competitors penetrate rapidly. Valuations are accordingly conservative, emphasizing licensing deals or pipeline prospects for upside. Investment approaches should consider market entry timing, patent litigation outcomes, and pipeline advancements.

Expected market contraction could depress prices for publicly traded manufacturers. Conversely, early engagement with reformulations or new indications could provide growth points. Exit strategies include licensing or acquisition, depending on regulatory progress and patent protection.

Key Takeaways

• Ingenol mebutate is a niche dermatology treatment with approximately $250 million global sales in 2022.
• Patent expiration in 2026 introduces significant risk of generic competition; legal disputes are imminent.
• Existing competition from established AK treatments limits market growth prospects.
• Limited pipeline activity and high R&D costs hinder development of new formulations or indications.
• Investment risk increases sharply post-patent expiry, making licensing, reformulation, or pipeline progress critical for potential upside.

FAQs

1. How long will ingenol mebutate remain commercially viable?
Current approval extends until at least 2026, with limited indications. Post-patent expiry, sales may decline unless new formulations or uses are approved.

2. What are the primary competitors for ingenol mebutate?
Top competitors include 5-fluorouracil, imiquimod, and diclofenac gels. They are widely used, less expensive, and have longer-standing safety data.

3. Are there opportunities for investment in ingenol mebutate reformulations?
Yes. Reformulation efforts, such as liposomal delivery, could extend exclusivity and improve efficacy, but involve high R&D costs and regulatory hurdles.

4. What is the potential impact of patent litigation?
Patent disputes can delay generic entry and extend commercial exclusivity. However, legal uncertainties pose investment risks.

5. How should investors approach this asset?
Focus on pipeline development, licensing potential, or reformulation opportunities. Post-2026, prepare for attrition due to generics unless new formulations or indications are successfully introduced.

---

Sources
[1] Global Data, "Topicals Market Report," 2022.
[2] LEO Pharma, "Ingenol Mebutate Product Information," 2023.
[3] FDA, "Drug Approval History," 2022.
[4] MarketWatch, "Actinic Keratosis Treatment Market," August 2022.